The Balancing Act® Airing on Lifetime TV Discusses Biomarker Testing in Lung Cancer
Boehringer Ingelheim Sponsors Segment on March 21st Show to Help Raise Awareness of Biomarker Testing in Lung Cancer
(Pompano Beach, FL – CISION – March 20, 2013) Award-winning popular morning show The Balancing Act®, airing on Lifetime® TV, will feature a segment sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. to discuss biomarker testing in lung cancer on Friday, March 21 at 7:00 a.m. (ET/PT). Make sure to tune in as The Balancing Act hosts help jump start the day with animated conversation and trusted information to empower a woman’s life.
Don’t miss this featured segment taking center stage on The Balancing Act:
-
Importance of Biomarker Testing in Lung Cancer Brought to You by Boehringer Ingelheim
The diagnosis of lung cancer is rapidly changing, as nearly a quarter of advanced non-small cell lung cancer patients have a biomarker that can help identify appropriate treatments. Join Drs. Gary Palmer and Deborah Morosini of Foundation Medicine as they share insights into a multidisciplinary healthcare provider approach to biomarker testing in lung cancer. Further, you’ll learn how biomarkers and biomarker testing are important elements in the fight against lung cancer.
“BI is committed to providing healthcare professionals involved in the diagnosis and treatment of lung cancer with education about biomarker testing,” said Kevin Lokay, vice president and business unit head of oncology, Boehringer Ingelheim Pharmaceuticals, Inc. “By testing for biomarkers immediately following a lung cancer diagnosis, healthcare professionals will have the opportunity to identify a treatment regimen that is most appropriate for their patient’s particular cancer. Healthcare professionals can visit LetsTestNow.com for more information.”
About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.
Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to discover and develop innovative cancer treatments. Working in close collaboration with the international scientific community and a number of the world’s leading cancer centers, Boehringer Ingelheim’s commitment to oncology is underpinned by using advances in science to develop a range of targeted therapies for various solid tumors and hematological cancers. The current focus of late-stage research includes compounds in three areas: signal transduction inhibition, angiogenesis inhibition and cell-cycle kinase inhibition. The company is also evaluating a robust and growing pipeline of early-stage oncology compounds in areas including growth/survival signaling, immunotherapy and epigenetics.
For information about participating in a Boehringer Ingelheim clinical trial, please visit www.bicancertrials.com or call 1.866.725.7110. Healthcare providers interested in learning more about Boehringer Ingelheim clinical trials in oncology can visit www.inoncologyus.com for additional information.
For more information please visit www.boehringer-ingelheim.com.
About The Balancing Act® airing on Lifetime Television
Now in its 6th year, The Balancing Act® continues to empower women in all aspects of their lives. The mission at The Balancing Act is simple - the show strives to help today’s modern woman balance it all by bringing them exceptional solutions to everyday problems. Entertaining, educational and trusted by women, viewers can tune in to America’s premier morning show The Balancing Act on weekday mornings at 7:00 am (ET/PT) airing on Lifetime television. For additional information or to view a segment visit: www.thebalancingact.com
For more information regarding O2 Media Inc. Branded Entertainment, Product Placement and TV Brand Integration go to: http://o2mediainc.com/Pages/187/Branded-Entertainment
Join the Conversation!
Like us on Facebook
Follow us on Twitter
Watch us on YouTube
Media Contact:
O2 Media, Inc.
pamela@o2mediainc.com
(954) 691-1102
Tags:
